News

In his 10 months on the job, Commissioner Scott Gottlieb of the U.S. Food and Drug Administration is earning praise for his efforts to make clinical trials for new therapies more flexible and responsive to the needs of rare disease patients. From cystic fibrosis to epidermolysis bullosa, the FDA…

At a time of unprecedented polarization in Congress, two U.S. lawmakers — one Republican, one Democrat — are stressing the urgency of working across the aisle to help the estimated 30 million Americans with rare diseases. Rep. Leonard Lance (R-New Jersey) and Sen. Amy Klobuchar (D-Minnesota) spoke to more…

Boston-based FDNA has launched a global initiative to promote medical research collaborations and to develop new precision approaches for diagnosing and treating disease, including Angelman syndrome. The initiative, called Genomics Collaborative, uses computer analysis and artificial intelligence technologies to integrate genetic information with the physical and biological characteristics of a particular disease.

An older existing medication that targets a pathway thought to be involved in fragile X syndrome failed to reverse any behavioral characteristics in mouse models of the disease, and was found to further compromise social skills in the mice. The therapy, rapamycin (also called sirolimus, brand name Rapamune),…

A mutation in the TSC2 gene leads to lower-than-usual levels of the fragile X mental retardation protein (FMRP) and its nerve cell targets, and might be of relevance to autism spectrum-related genetic disorders like fragile X, researchers report. Their study, “Purkinje cells derived from TSC patients display hypoexcitability and synaptic…

Retrophin and the U.S. subsidiary of Britain’s Horizon Pharma will each donate $3 million over a six-year period to the Rare Disease Institute (RDI) at Children’s National Health System in Washington, D.C., helping it to strengthen care available and expand as a “center of excellence” for rare…

GW Pharmaceuticals is going to increase its focus on the development of its investigational, cannabinoid-based therapy GWP42006 to treat autism spectrum disorders (ASD), including Fragile X, the company announced. According to a press release, the company’s decision is based on recent results of a clinical trial in…

Carriers of the fragile X premutation who have not yet developed the disease have slower motor movements associated with mutation length and increased age. The study, “Age- and CGG Repeat-Related Slowing of Manual Movement in Fragile X Carriers: A Prodrome of Fragile X-Associated Tremor Ataxia Syndrome?” was published in the…

In recognition of Rare Disease Day 2018, Bionews Services — which publishes this website — will attend and report on three relevant conferences in the U.S. dealing with policies and programs of importance to patients and their families. The three are among 50 events in 32 states…

The University of California at Davis’s MIND Institute is recruiting children and young adults with fragile X syndrome for clinical trials dealing with learning spoken language. A key focus of the studies will be exploring ways to help them with these problems.